MétaCan
Menu
Back to cohort
Record W4411715496 · doi:10.6004/jnccn.2025.7029

Association of Polypharmacy and Potentially Inappropriate Medications With Outcomes in Older Adults With DLBCL: A Population Study

2025· article· en· W4411715496 on OpenAlexaff
Inna Y. Gong, Abi Vijenthira, Zharmaine Ante, Andrew Calzavara, Tammy T. Hshieh, Clark DuMontier, Gregory A. Abel, Jane A. Driver, Shabbir M.H. Alibhai, Anca Prica, Matthew C. Cheung, Lee Mozessohn

Bibliographic record

VenueJournal of the National Comprehensive Cancer Network · 2025
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Research Studies
Canadian institutionsHealth Sciences CentreUniversity of TorontoUniversity Health NetworkSunnybrook Health Science CentreInstitute for Clinical Evaluative SciencesPrincess Margaret Cancer Centre
Fundersnot available
KeywordsMedicinePolypharmacyHazard ratioInternal medicinePopulationComorbidityProportional hazards modelEmergency medicineConfidence intervalEnvironmental health

Abstract

fetched live from OpenAlex

BACKGROUND: Polypharmacy and potentially inappropriate medications (PIMs) may be associated with survival and health care utilization in older patients undergoing treatment for diffuse large B-cell lymphoma (DLBCL). METHODS: This population-based study examined patients with DLBCL aged ≥66 years receiving rituximab-based therapy from January 1, 2006, to December 31, 2017, and followed them until March 31, 2019. Polypharmacy was defined as taking ≥5 or ≥8 concurrent medications within 90 days of treatment initiation. PIMs were assessed using the Anticholinergic Risk Scale (ARS) and the Geriatric Oncology Potentially Inappropriate Medications (GO-PIM) scale. Cox regression and negative binomial models were conducted, adjusting for age, sex, frailty, and comorbidity burden (Aggregated Diagnosis Groups [ADGs]). The primary outcome was all-cause mortality, and the secondary outcome was health care utilization, measured by unplanned emergency department visits and hospitalizations. RESULTS: A total of 5,527 patients were included (median age, 75 years; 48% female), of whom 69% and 40% had polypharmacy defined as ≥5 and ≥8 medications, respectively. In terms of PIMs, 27% of patients had at least one PIM based on ARS, whereas 70% had a high-risk medication based on the GO-PIM scale. Polypharmacy was associated with increased risk of all-cause mortality in the adjusted analysis, with an adjusted hazard ratio (aHR) of 1.14 (95% CI, 1.05-1.23; P=.0021) for patients taking ≥5 medications, and 1.18 (95% CI, 1.09-1.27; P<.0001) for those taking ≥8 medications. Increasing number of PIMs was associated with increased mortality risk. Polypharmacy was associated with an increased relative risk of health care utilization, with an adjusted rate ratio (aRR) of 1.14 (95% CI, 1.06-1.22; P=.0004) for patients taking ≥5 medications, and 1.16 (95% CI, 1.08-1.24; P<.0001) for those taking ≥8 medications. For PIMs, a higher score on the GO-PIM scale was associated with greater risk of health care utilization (aRR for ≥3 medications, 1.20; 95% CI, 1.09-1.32; P=.0003), whereas ARS was not. CONCLUSIONS: Polypharmacy and PIMs are associated with an increased relative risk of mortality and health care utilization among older adults with DLBCL undergoing treatment, independent of frailty and comorbidity.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.012

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.357
Teacher spread0.341 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the National Comprehensive Cancer NetworkSame topicLung Cancer Research StudiesFrench-language works237,207